JP2013525331A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013525331A5 JP2013525331A5 JP2013505467A JP2013505467A JP2013525331A5 JP 2013525331 A5 JP2013525331 A5 JP 2013525331A5 JP 2013505467 A JP2013505467 A JP 2013505467A JP 2013505467 A JP2013505467 A JP 2013505467A JP 2013525331 A5 JP2013525331 A5 JP 2013525331A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- trans
- pharmaceutical composition
- compound according
- haloalkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 34
- 150000001875 compounds Chemical class 0.000 claims 31
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 125000003545 alkoxy group Chemical group 0.000 claims 17
- 125000004438 haloalkoxy group Chemical group 0.000 claims 17
- 125000001188 haloalkyl group Chemical group 0.000 claims 17
- 125000001475 halogen functional group Chemical group 0.000 claims 17
- 125000001424 substituent group Chemical group 0.000 claims 17
- 125000004093 cyano group Chemical group *C#N 0.000 claims 15
- -1 -CH 2 C (= O) NH 2 Chemical group 0.000 claims 14
- 150000001408 amides Chemical class 0.000 claims 11
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 11
- 238000011282 treatment Methods 0.000 claims 8
- 101001050886 Homo sapiens Lysine-specific histone demethylase 1A Proteins 0.000 claims 7
- 102100024985 Lysine-specific histone demethylase 1A Human genes 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 230000002265 prevention Effects 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 5
- 108010062431 Monoamine oxidase Proteins 0.000 claims 4
- 229940124639 Selective inhibitor Drugs 0.000 claims 4
- 208000036142 Viral infection Diseases 0.000 claims 4
- 125000001931 aliphatic group Chemical group 0.000 claims 4
- 125000004104 aryloxy group Chemical group 0.000 claims 4
- 125000002837 carbocyclic group Chemical group 0.000 claims 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 4
- 230000009385 viral infection Effects 0.000 claims 4
- 125000004442 acylamino group Chemical group 0.000 claims 3
- 125000003282 alkyl amino group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 125000005018 aryl alkenyl group Chemical group 0.000 claims 3
- 125000005015 aryl alkynyl group Chemical group 0.000 claims 3
- 125000005110 aryl thio group Chemical group 0.000 claims 3
- 125000004452 carbocyclyl group Chemical group 0.000 claims 3
- 125000001651 cyanato group Chemical group [*]OC#N 0.000 claims 3
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 3
- 125000005366 cycloalkylthio group Chemical group 0.000 claims 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 125000003106 haloaryl group Chemical group 0.000 claims 3
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 3
- 125000005368 heteroarylthio group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 125000000858 thiocyanato group Chemical group *SC#N 0.000 claims 3
- 241001529453 unidentified herpesvirus Species 0.000 claims 3
- 102100028661 Amine oxidase [flavin-containing] A Human genes 0.000 claims 2
- 102100028116 Amine oxidase [flavin-containing] B Human genes 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 208000029433 Herpesviridae infectious disease Diseases 0.000 claims 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 206010057644 Testis cancer Diseases 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000003368 amide group Chemical group 0.000 claims 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 125000005114 heteroarylalkoxy group Chemical group 0.000 claims 2
- 238000011534 incubation Methods 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 230000007420 reactivation Effects 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- 125000005423 trihalomethanesulfonamido group Chemical group 0.000 claims 2
- 230000007419 viral reactivation Effects 0.000 claims 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims 1
- JXFCSNCFHXWKCF-XZOQPEGZSA-N (1r,2s)-2-[4-(3-chlorophenyl)phenyl]-n-(2-cyclohexylethyl)cyclopropan-1-amine Chemical compound ClC1=CC=CC(C=2C=CC(=CC=2)[C@H]2[C@@H](C2)NCCC2CCCCC2)=C1 JXFCSNCFHXWKCF-XZOQPEGZSA-N 0.000 claims 1
- DKXFGPJMRWQEJZ-XZOQPEGZSA-N (1r,2s)-2-[4-(4-chlorophenyl)phenyl]-n-(2-cyclohexylethyl)cyclopropan-1-amine Chemical compound C1=CC(Cl)=CC=C1C1=CC=C([C@H]2[C@@H](C2)NCCC2CCCCC2)C=C1 DKXFGPJMRWQEJZ-XZOQPEGZSA-N 0.000 claims 1
- OMLUSVPZLJACMT-BJKOFHAPSA-N (1r,2s)-2-[4-[(3-bromophenyl)methoxy]phenyl]-n-(2-cyclohexylethyl)cyclopropan-1-amine Chemical compound BrC1=CC=CC(COC=2C=CC(=CC=2)[C@H]2[C@@H](C2)NCCC2CCCCC2)=C1 OMLUSVPZLJACMT-BJKOFHAPSA-N 0.000 claims 1
- BGTYDVHTSKDFPF-ZWKOTPCHSA-N (1r,2s)-n-(2-cycloheptylethyl)-2-phenylcyclopropan-1-amine Chemical compound N([C@H]1[C@@H](C1)C=1C=CC=CC=1)CCC1CCCCCC1 BGTYDVHTSKDFPF-ZWKOTPCHSA-N 0.000 claims 1
- KHTQKTORDGNBRF-BJKOFHAPSA-N (1r,2s)-n-(2-cyclohexylethyl)-2-[4-(3-methoxyphenyl)phenyl]cyclopropan-1-amine Chemical compound COC1=CC=CC(C=2C=CC(=CC=2)[C@H]2[C@@H](C2)NCCC2CCCCC2)=C1 KHTQKTORDGNBRF-BJKOFHAPSA-N 0.000 claims 1
- CUUAZVAEZZVJPO-ZWKOTPCHSA-N (1r,2s)-n-(3-cyclohexylpropyl)-2-phenylcyclopropan-1-amine Chemical compound C1([C@@H]2C[C@H]2NCCCC2CCCCC2)=CC=CC=C1 CUUAZVAEZZVJPO-ZWKOTPCHSA-N 0.000 claims 1
- YHNQRLPXWDLVDN-QNRWSGHRSA-N 4,5-dimethoxy-n-[(1r,2s)-2-(4-phenylmethoxyphenyl)cyclopropyl]-2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC([C@@H]2C[C@H]2NC2C3=CC=C(C(=C3CC2)OC)OC)=CC=C1OCC1=CC=CC=C1 YHNQRLPXWDLVDN-QNRWSGHRSA-N 0.000 claims 1
- UPLFFRCQYPKTOS-DEWJTGPOSA-N 5,6-dimethoxy-n-[(1r,2s)-2-(4-phenylmethoxyphenyl)cyclopropyl]-2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC([C@@H]2C[C@H]2NC2CCC=3C=C(C(=CC=32)OC)OC)=CC=C1OCC1=CC=CC=C1 UPLFFRCQYPKTOS-DEWJTGPOSA-N 0.000 claims 1
- XYCRGAPMMXRAJL-PXKIYYGHSA-N 6-chloro-n-[(1r,2s)-2-phenylcyclopropyl]-2,3-dihydro-1h-inden-1-amine Chemical compound C1([C@@H]2C[C@H]2NC2CCC3=CC=C(C=C32)Cl)=CC=CC=C1 XYCRGAPMMXRAJL-PXKIYYGHSA-N 0.000 claims 1
- GTUTWJPRKOCKAP-KCIKGWAESA-N 6-methoxy-n-[(1r,2s)-2-(4-phenylmethoxyphenyl)cyclopropyl]-2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC([C@@H]2C[C@H]2NC2CCC3=CC=C(C=C32)OC)=CC=C1OCC1=CC=CC=C1 GTUTWJPRKOCKAP-KCIKGWAESA-N 0.000 claims 1
- YEZIEPBYZJECGY-KCIKGWAESA-N 6-methoxy-n-[(1r,2s)-2-[4-(3-methoxyphenyl)phenyl]cyclopropyl]-2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC([C@@H]2C[C@H]2NC2CCC3=CC=C(C=C32)OC)=CC=C1C1=CC=CC(OC)=C1 YEZIEPBYZJECGY-KCIKGWAESA-N 0.000 claims 1
- NEABQLUIWQPBNJ-LJJQOFDWSA-N 6-methoxy-n-[(1r,2s)-2-phenylcyclopropyl]-2,3-dihydro-1h-inden-1-amine Chemical compound C1([C@@H]2C[C@H]2NC2CCC3=CC=C(C=C32)OC)=CC=CC=C1 NEABQLUIWQPBNJ-LJJQOFDWSA-N 0.000 claims 1
- HEJHLIFIPMUHJZ-DRXLFZDCSA-N 7-methoxy-n-[(1r,2s)-2-(4-phenylmethoxyphenyl)cyclopropyl]-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=CC([C@@H]2C[C@H]2NC2CCCC3=CC=C(C=C32)OC)=CC=C1OCC1=CC=CC=C1 HEJHLIFIPMUHJZ-DRXLFZDCSA-N 0.000 claims 1
- BWWMRSAGHGFIDQ-SJBAFXMYSA-N 7-methoxy-n-[(1r,2s)-2-phenylcyclopropyl]-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1([C@@H]2C[C@H]2NC2CCCC3=CC=C(C=C32)OC)=CC=CC=C1 BWWMRSAGHGFIDQ-SJBAFXMYSA-N 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 claims 1
- 125000006317 cyclopropyl amino group Chemical group 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000001261 isocyanato group Chemical group *N=C=O 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- IWZGJIQMVRUHPI-UHFFFAOYSA-N n-(2-phenylcyclopropyl)-6,11-dihydro-5h-dibenzo[1,2-a:1',2'-e][7]annulen-11-amine Chemical compound C1C(NC2C3=CC=CC=C3CCC3=CC=CC=C32)C1C1=CC=CC=C1 IWZGJIQMVRUHPI-UHFFFAOYSA-N 0.000 claims 1
- PLYANGBAOXRROA-UHFFFAOYSA-N n-(2-phenylcyclopropyl)cyclopentanamine Chemical compound C=1C=CC=CC=1C1CC1NC1CCCC1 PLYANGBAOXRROA-UHFFFAOYSA-N 0.000 claims 1
- DHZITQRRQYOFRP-QNRWSGHRSA-N n-[(1r,2s)-2-[4-(3-chlorophenyl)phenyl]cyclopropyl]-6-methoxy-2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC([C@@H]2C[C@H]2NC2CCC3=CC=C(C=C32)OC)=CC=C1C1=CC=CC(Cl)=C1 DHZITQRRQYOFRP-QNRWSGHRSA-N 0.000 claims 1
- LTCCTDWUXLBMOZ-QNRWSGHRSA-N n-[(1r,2s)-2-[4-(4-chlorophenyl)phenyl]cyclopropyl]-6-methoxy-2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC([C@@H]2C[C@H]2NC2CCC3=CC=C(C=C32)OC)=CC=C1C1=CC=C(Cl)C=C1 LTCCTDWUXLBMOZ-QNRWSGHRSA-N 0.000 claims 1
- FIHPHWRNHZMRQA-KCIKGWAESA-N n-[(1r,2s)-2-[4-[(3-bromophenyl)methoxy]phenyl]cyclopropyl]-6-methoxy-2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC([C@@H]2C[C@H]2NC2CCC3=CC=C(C=C32)OC)=CC=C1OCC1=CC=CC(Br)=C1 FIHPHWRNHZMRQA-KCIKGWAESA-N 0.000 claims 1
- YPFUZAOHQYLSHW-PXKIYYGHSA-N n-[(1r,2s)-2-phenylcyclopropyl]-2,3-dihydro-1h-inden-1-amine Chemical compound C1([C@H]2[C@H](NC3C4=CC=CC=C4CC3)C2)=CC=CC=C1 YPFUZAOHQYLSHW-PXKIYYGHSA-N 0.000 claims 1
- ISBBCWJDLSIJAX-PXKIYYGHSA-N n-[(1r,2s)-2-phenylcyclopropyl]-6-(trifluoromethyl)-2,3-dihydro-1h-inden-1-amine Chemical compound C1([C@@H]2C[C@H]2NC2CCC3=CC=C(C=C32)C(F)(F)F)=CC=CC=C1 ISBBCWJDLSIJAX-PXKIYYGHSA-N 0.000 claims 1
- YPEIHBUSSOFCJK-LSDHHAIUSA-N n-[(1r,2s)-2-phenylcyclopropyl]cyclohexanamine Chemical compound N([C@@H]1C[C@H]1C=1C=CC=CC=1)C1CCCCC1 YPEIHBUSSOFCJK-LSDHHAIUSA-N 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10160315 | 2010-04-19 | ||
| EP10160315.7 | 2010-04-19 | ||
| PCT/EP2011/056279 WO2011131697A1 (en) | 2010-04-19 | 2011-04-19 | Lysine specific demethylase-1 inhibitors and their use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013525331A JP2013525331A (ja) | 2013-06-20 |
| JP2013525331A5 true JP2013525331A5 (enExample) | 2014-06-05 |
| JP5868948B2 JP5868948B2 (ja) | 2016-02-24 |
Family
ID=44280905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013505467A Expired - Fee Related JP5868948B2 (ja) | 2010-04-19 | 2011-04-19 | リジン特異的脱メチル化酵素１阻害薬およびその使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US8722743B2 (enExample) |
| EP (2) | EP2560947B1 (enExample) |
| JP (1) | JP5868948B2 (enExample) |
| KR (1) | KR101794020B1 (enExample) |
| CN (1) | CN102947265B (enExample) |
| AU (1) | AU2011244325B2 (enExample) |
| BR (2) | BR122019020471B1 (enExample) |
| CA (1) | CA2796726C (enExample) |
| CY (1) | CY1118344T1 (enExample) |
| DK (1) | DK2560947T3 (enExample) |
| ES (1) | ES2607081T3 (enExample) |
| HR (1) | HRP20161748T1 (enExample) |
| HU (1) | HUE030938T2 (enExample) |
| IL (1) | IL222361A (enExample) |
| LT (1) | LT2560947T (enExample) |
| MX (1) | MX2012012111A (enExample) |
| PL (1) | PL2560947T3 (enExample) |
| PT (1) | PT2560947T (enExample) |
| RS (1) | RS55348B1 (enExample) |
| RU (1) | RU2599248C2 (enExample) |
| SI (1) | SI2560947T1 (enExample) |
| WO (1) | WO2011131697A1 (enExample) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2361242B1 (en) | 2008-10-17 | 2018-08-01 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
| WO2010084160A1 (en) | 2009-01-21 | 2010-07-29 | Oryzon Genomics S.A. | Phenylcyclopropylamine derivatives and their medical use |
| KR101736218B1 (ko) | 2009-09-25 | 2017-05-16 | 오리존 지노믹스 에스.에이. | 라이신 특이적 디메틸라아제-1 억제제 및 이의 용도 |
| EP2486002B1 (en) | 2009-10-09 | 2019-03-27 | Oryzon Genomics, S.A. | Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use |
| WO2011106574A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Inhibitors for antiviral use |
| US9186337B2 (en) | 2010-02-24 | 2015-11-17 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae |
| ES2607081T3 (es) * | 2010-04-19 | 2017-03-29 | Oryzon Genomics, S.A. | Inhibidores de desmetilasa específica de lisina-1 y su uso |
| US9006449B2 (en) | 2010-07-29 | 2015-04-14 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as LSD1 inhibitors |
| LT2598482T (lt) | 2010-07-29 | 2018-07-10 | Oryzon Genomics, S.A. | Demetilazės lsd1 inhibitoriai arilciklopropilamino pagrindu ir jų medicininis panaudojimas |
| US20130303545A1 (en) * | 2010-09-30 | 2013-11-14 | Tamara Maes | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| US9061966B2 (en) | 2010-10-08 | 2015-06-23 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
| US20140163041A1 (en) | 2011-02-08 | 2014-06-12 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders |
| WO2012107498A1 (en) | 2011-02-08 | 2012-08-16 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
| CN103857393B (zh) * | 2011-03-25 | 2016-08-17 | 葛兰素史密斯克莱知识产权（第2号）有限公司 | 环丙基胺作为lsd1抑制剂 |
| WO2012156531A2 (en) | 2011-05-19 | 2012-11-22 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for inflammatory diseases or conditions |
| WO2012156537A2 (en) | 2011-05-19 | 2012-11-22 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for thrombosis and cardiovascular diseases |
| SI2776394T1 (sl) * | 2011-10-20 | 2019-05-31 | Oryzon Genomics, S.A. | Spojine (hetero)aril ciklopropilamina kot inhibitorji LSD1 |
| EP3736265A1 (en) * | 2011-10-20 | 2020-11-11 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
| CN105051005B (zh) | 2012-10-12 | 2017-06-13 | 武田药品工业株式会社 | 环丙胺化合物及其用途 |
| CN103242171A (zh) * | 2013-05-09 | 2013-08-14 | 苏州明锐医药科技有限公司 | 反式-(1r,2s)-2-(3,4-二氟苯基)环丙胺的制备方法 |
| WO2015021128A1 (en) | 2013-08-06 | 2015-02-12 | Imago Biosciences Inc. | Kdm1a inhibitors for the treatment of disease |
| EP3102034A4 (en) * | 2014-02-07 | 2017-07-12 | MUSC Foundation For Research Development | Aminotriazole- and aminotetrazole-based kdm1a inhibitors as epigenetic modulators |
| WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| PE20161573A1 (es) | 2014-02-13 | 2017-01-19 | Incyte Corp | Ciclopropilamina como inhibidor de la lsd1 |
| WO2015123408A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| TWI664164B (zh) | 2014-02-13 | 2019-07-01 | 美商英塞特控股公司 | 作為ｌｓｄ１抑制劑之環丙胺 |
| CN106459024B (zh) | 2014-04-11 | 2019-11-05 | 武田药品工业株式会社 | 环丙胺化合物及其用途 |
| US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
| US9695168B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors |
| US10485772B2 (en) | 2014-08-25 | 2019-11-26 | EpiAxis Therapeutics Pty Ltd. | Compositions for modulating cancer stem cells and uses therefor |
| PL3256218T3 (pl) | 2015-02-12 | 2025-03-31 | Imago Biosciences Inc. | Inhibitor kdm1a i jego zastosowanie w terapii |
| MY191796A (en) | 2015-04-03 | 2022-07-15 | Incyte Corp | Heterocyclic compounds as lsd1 inhibitors |
| EP3090998A1 (en) | 2015-05-06 | 2016-11-09 | F. Hoffmann-La Roche AG | Solid forms |
| WO2016198649A1 (en) | 2015-06-12 | 2016-12-15 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| EP3307267B1 (en) | 2016-06-10 | 2019-04-10 | Oryzon Genomics, S.A. | Multiple sclerosis treatment |
| WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| KR102710120B1 (ko) | 2015-08-12 | 2024-09-27 | 인사이트 홀딩스 코포레이션 | Lsd1 저해제의 염 |
| US10059668B2 (en) | 2015-11-05 | 2018-08-28 | Mirati Therapeutics, Inc. | LSD1 inhibitors |
| KR102720551B1 (ko) | 2015-12-29 | 2024-10-21 | 미라티 테라퓨틱스, 인크. | Lsd1 억제제 |
| AU2017233898B2 (en) | 2016-03-15 | 2022-12-15 | Oryzon Genomics, S.A. | Combinations of LSD1 inhibitors for use in the treatment of solid tumors |
| KR102646126B1 (ko) | 2016-03-15 | 2024-03-11 | 오리존 지노믹스 에스.에이. | 혈액 악성 종양의 치료를 위한 lsd1 억제제의 조합물 |
| CN107200706A (zh) * | 2016-03-16 | 2017-09-26 | 中国科学院上海药物研究所 | 一类氟取代的环丙胺类化合物及其制备方法、药物组合物和用途 |
| ES3042059T3 (en) | 2016-03-16 | 2025-11-18 | Oryzon Genomics Sa | Methods to determine kdm1a target engagement and chemoprobes useful therefor |
| PE20190377A1 (es) | 2016-04-22 | 2019-03-08 | Incyte Corp | Formulaciones de un inhibidor de lsd 1 |
| CN111194306B (zh) | 2016-08-16 | 2023-05-16 | 伊美格生物科学公司 | 用于制备kdm1a抑制剂的方法和过程 |
| US20190256929A1 (en) | 2016-11-03 | 2019-08-22 | Oryzon Genomics, S.A. | Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents |
| EP3535420A1 (en) | 2016-11-03 | 2019-09-11 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
| WO2018106984A1 (en) | 2016-12-09 | 2018-06-14 | Constellation Pharmaceuticals, Inc. | Markers for personalized cancer treatment with lsd1 inhibitors |
| RU2763898C9 (ru) * | 2017-01-24 | 2022-03-18 | Цспц Чжунци Фармасьютикал Текнолоджи (Шицзячжуан) Ко., Лтд. | Ингибитор lsd1, а также способ его получения и его применение |
| JP2020152641A (ja) * | 2017-07-07 | 2020-09-24 | 国立研究開発法人理化学研究所 | リジン特異的脱メチル化酵素１阻害活性を有する新規化合物、その製造方法及びその用途 |
| EP3658276A1 (en) * | 2017-07-26 | 2020-06-03 | SABIC Global Technologies B.V. | Composite sorbent, devices, and methods |
| MY204406A (en) | 2017-08-03 | 2024-08-27 | Oryzon Genomics Sa | Methods of treating behavior alterations |
| WO2019068326A1 (en) | 2017-10-05 | 2019-04-11 | Université D'aix-Marseille | INHIBITORS OF LSD1 FOR THE TREATMENT AND PREVENTION OF CARDIOMYOPATHIES |
| JP7450559B2 (ja) | 2018-05-11 | 2024-03-15 | イマーゴ バイオサイエンシーズ インコーポレイテッド | 疾患の処置のためのｋｄｍ１ａ阻害剤 |
| CN112424175B (zh) * | 2018-07-20 | 2022-10-28 | 石药集团中奇制药技术（石家庄）有限公司 | 一种lsd1抑制剂的盐及其晶型 |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| CN112689638B (zh) * | 2018-09-13 | 2022-11-08 | 南昌弘益药业有限公司 | 作为lsd1抑制剂的环丙胺类化合物及其应用 |
| BR112021016064A2 (pt) | 2019-03-20 | 2021-10-05 | Oryzon Genomics, S.A. | Métodos de tratamento do transtorno de personalidade borderline |
| CN120837494A (zh) | 2019-03-20 | 2025-10-28 | 奥莱松基因组股份有限公司 | 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法 |
| JP2022546908A (ja) | 2019-07-05 | 2022-11-10 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｋｄｍ１ａ阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法 |
| IT202000007873A1 (it) * | 2020-04-14 | 2021-10-14 | St Europeo Di Oncologia S R L | Molecole per uso nel trattamento delle infezioni virali |
| WO2021228146A1 (zh) * | 2020-05-12 | 2021-11-18 | 石药集团中奇制药技术（石家庄）有限公司 | 一种lsd1抑制剂的用途 |
| EP3964204A1 (en) | 2020-09-08 | 2022-03-09 | Université d'Aix-Marseille | Lsd1 inhibitors for use in the treatment and prevention of fibrosis of tissues |
| CN112451671B (zh) * | 2020-12-02 | 2021-11-02 | 武汉大学 | KDM1A在抑制RNA病毒刺激下干扰素IFNβ表达中的应用 |
| CN113750095B (zh) * | 2021-03-10 | 2023-07-04 | 中国医学科学院医药生物技术研究所 | 含有环丙基骨架的化合物在制备治疗和/或预防冠状病毒感染药物中的应用 |
| CA3231846A1 (en) | 2021-04-08 | 2022-10-13 | Tamara Maes | Combinations of lsd1 inhibitors for treating myeloid cancers |
| EP4522136A1 (en) | 2022-05-09 | 2025-03-19 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
| CN119497613A (zh) | 2022-05-09 | 2025-02-21 | 奥莱松基因组股份有限公司 | 使用lsd1抑制剂治疗nf1-突变肿瘤的方法 |
| AU2023385514A1 (en) | 2022-11-24 | 2025-07-10 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors and menin inhibitors for treating cancer |
Family Cites Families (127)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3106578A (en) | 1960-09-16 | 1963-10-08 | Smith Kline French Lab | Nu-phenethyl-2-phenylcyclopropylamine derivatives |
| US3365458A (en) | 1964-06-23 | 1968-01-23 | Aldrich Chem Co Inc | N-aryl-n'-cyclopropyl-ethylene diamine derivatives |
| US3532749A (en) * | 1965-05-11 | 1970-10-06 | Aldrich Chem Co Inc | N'-propargyl-n**2-cyclopropyl-ethylenediamines and the salts thereof |
| US3471522A (en) | 1967-09-29 | 1969-10-07 | Aldrich Chem Co Inc | N-cyclopropyl-n'-furfuryl-n'-methyl ethylene diamines |
| US3532712A (en) | 1967-09-29 | 1970-10-06 | Aldrich Chem Co Inc | N'-cyclopropyl ethylenediamine derivatives |
| US3654306A (en) | 1970-01-26 | 1972-04-04 | Robins Co Inc A H | 5-azaspiro(2.4)heptane-4 6-diones |
| US3758684A (en) | 1971-09-07 | 1973-09-11 | Burroughs Wellcome Co | Treating dna virus infections with amino purine derivatives |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4409243A (en) | 1981-11-09 | 1983-10-11 | Julian Lieb | Treatment of auto-immune and inflammatory diseases |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| GB9311282D0 (en) | 1993-06-01 | 1993-07-21 | Rhone Poulenc Rorer Ltd | New compositions of matter |
| NZ297157A (en) | 1994-10-21 | 1999-08-30 | Nps Pharma Inc | Amine derivatives with calcium ion receptor activity; medicaments containing such compounds |
| US5652258A (en) * | 1995-05-30 | 1997-07-29 | Gliatech, Inc. | 2-(4-imidazoyl) cyclopropyl derivatives |
| US20040132820A1 (en) | 1996-02-15 | 2004-07-08 | Jean Gosselin | Agents with leukotriene B4-like antiviral (DNA) and anti-neoplastic activities |
| GB9615730D0 (en) | 1996-07-26 | 1996-09-04 | Medical Res Council | Anti-viral agent 1 |
| US5961987A (en) | 1996-10-31 | 1999-10-05 | University Of Iowa Research Foundation | Ocular protein stimulants |
| DE19647615A1 (de) | 1996-11-18 | 1998-05-20 | Bayer Ag | Verfahren zur Herstellung von Cyclopropylaminen |
| SE9702772D0 (sv) | 1997-07-22 | 1997-07-22 | Astra Pharma Prod | Novel compounds |
| AR017014A1 (es) | 1997-07-22 | 2001-08-22 | Astrazeneca Ab | Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos |
| AU1631699A (en) | 1997-12-18 | 1999-07-05 | E.I. Du Pont De Nemours And Company | Cyclohexylamine arthropodicides and fungicides |
| US6809120B1 (en) | 1998-01-13 | 2004-10-26 | University Of Saskatchewan Technologies Inc. | Composition containing propargylamine for enhancing cancer therapy |
| EP1071752B1 (en) | 1998-04-21 | 2003-07-09 | Micromet AG | CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF |
| SE9802206D0 (sv) * | 1998-06-22 | 1998-06-22 | Astra Pharma Inc | Novel compounds |
| TWI229674B (en) | 1998-12-04 | 2005-03-21 | Astra Pharma Prod | Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses |
| JP4574112B2 (ja) | 2000-05-26 | 2010-11-04 | シェーリング コーポレイション | アデノシンａ２ａレセプターアンタゴニスト |
| JP2001354563A (ja) | 2000-06-09 | 2001-12-25 | Sankyo Co Ltd | 置換ベンジルアミン類を含有する医薬 |
| US8519005B2 (en) | 2000-07-27 | 2013-08-27 | Thomas N. Thomas | Compositions and methods to prevent toxicity of antiinflammatory agents and enhance their efficacy |
| EP1193268A1 (en) | 2000-09-27 | 2002-04-03 | Applied Research Systems ARS Holding N.V. | Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases |
| PL364580A1 (en) | 2001-03-29 | 2004-12-13 | Bristol-Myers Squibb Company | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors |
| DE10123163A1 (de) | 2001-05-09 | 2003-01-16 | Gruenenthal Gmbh | Substituierte Cyclohexan-1,4-diaminderivate |
| US20030008844A1 (en) | 2001-05-17 | 2003-01-09 | Keryx Biopharmaceuticals, Inc. | Use of sulodexide for the treatment of inflammatory bowel disease |
| AU2003222786A1 (en) | 2002-04-18 | 2003-10-27 | Ucb, S.A. | Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions |
| US7704995B2 (en) | 2002-05-03 | 2010-04-27 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| EP1501514B1 (en) | 2002-05-03 | 2012-12-19 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| US7312214B2 (en) | 2002-05-10 | 2007-12-25 | Bristol-Myers Squibb Company | 1, 1-disubstituted cycloalkyl derivatives as factor Xa inhibitors |
| US20040033986A1 (en) | 2002-05-17 | 2004-02-19 | Protopopova Marina Nikolaevna | Anti tubercular drug: compositions and methods |
| US6951961B2 (en) | 2002-05-17 | 2005-10-04 | Marina Nikolaevna Protopopova | Methods of use and compositions for the diagnosis and treatment of infectious disease |
| US7456222B2 (en) | 2002-05-17 | 2008-11-25 | Sequella, Inc. | Anti tubercular drug: compositions and methods |
| DE60336550D1 (de) | 2002-05-20 | 2011-05-12 | Bristol Myers Squibb Co | Inhibitoren des hepatitis-c-virus |
| US7611704B2 (en) | 2002-07-15 | 2009-11-03 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
| SE0202539D0 (sv) | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
| WO2004055010A2 (en) | 2002-12-13 | 2004-07-01 | Smithkline Beecham Corporation | Cyclopropyl compounds as ccr5 antagonists |
| AU2004204760C1 (en) | 2003-01-08 | 2010-08-19 | Novartis Vaccines And Diagnostics, Inc. | Antibacterial agents |
| US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| GB0303439D0 (en) | 2003-02-14 | 2003-03-19 | Pfizer Ltd | Antiparasitic terpene alkaloids |
| US7186832B2 (en) | 2003-02-20 | 2007-03-06 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| DE602004023838D1 (de) | 2003-04-24 | 2009-12-10 | Merck & Co Inc | Hemmer der akt aktivität |
| WO2005009941A1 (en) | 2003-07-03 | 2005-02-03 | Eli Lilly And Company | Indane derivates as muscarinic receptor agonists |
| CN102060806A (zh) | 2003-09-11 | 2011-05-18 | iTherX药品公司 | 细胞因子抑制剂 |
| US7705052B2 (en) | 2003-09-12 | 2010-04-27 | Merck Serono Sa | Sulfonamide derivatives for the treatment of diabetes |
| CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| CN1871008A (zh) | 2003-10-21 | 2006-11-29 | 默克公司 | 用于治疗神经病变性疼痛的三唑并－哒嗪化合物和它们的衍生物 |
| US7026339B2 (en) | 2003-11-07 | 2006-04-11 | Fan Yang | Inhibitors of HCV NS5B polymerase |
| WO2005058884A2 (en) | 2003-12-15 | 2005-06-30 | Japan Tobacco Inc. | Cyclopropane compounds and pharmaceutical use thereof |
| EP1694638A1 (en) | 2003-12-15 | 2006-08-30 | Japan Tobacco, Inc. | N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof |
| SMP200600024B (it) | 2003-12-15 | 2006-07-19 | Almirall Prodesfarma Ag | 2,6-Biseteroaril-4-amminopirimidine come antagonisti del recettore dell'adenosina |
| US7399825B2 (en) | 2003-12-24 | 2008-07-15 | Lipps Binie V | Synthetic peptide, inhibitor to DNA viruses |
| BRPI0510319A (pt) | 2004-04-26 | 2007-10-16 | Pfizer | inibidores da enzima integrase de hiv |
| US20090275099A1 (en) | 2004-04-27 | 2009-11-05 | Regents Of The University Of Michigan | Methods and compositions for treating diseases and conditions associated with mitochondrial function |
| DE102004057594A1 (de) | 2004-11-29 | 2006-06-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substitueirte Pteridine zur Behandlung von entzündlichen Erkrankungen |
| US7741086B2 (en) | 2004-12-16 | 2010-06-22 | President And Fellows Of Harvard College | Histone demethylation mediated by the nuclear amine oxidase homolog LSD1 |
| DE602005022826D1 (de) | 2005-02-18 | 2010-09-23 | Universitaetsklinikum Freiburg | Kontrolle der Androgen Rezeptor-abhängigen Gen Expression durch Hemmung der Aminoxidase Aktivität der Lysin spezifischen Demethylase (LSD1) |
| US20060275366A1 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Controlled-release formulation |
| WO2007002220A2 (en) | 2005-06-21 | 2007-01-04 | Bristol-Myers Squibb Company | Aminoacetamide acyl guanidines as beta-secretase inhibitors |
| EP1741708A1 (en) | 2005-06-28 | 2007-01-10 | Sanofi-Aventis Deutschland GmbH | Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals |
| BRPI0613962A2 (pt) | 2005-07-25 | 2009-03-24 | Intermune Inc | inibidores macrocìclicos inovadores de replicação de vìrus da hepatite c |
| AU2006279943B2 (en) | 2005-08-10 | 2012-02-16 | The Johns Hopkins University | Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors |
| WO2007025144A1 (en) | 2005-08-24 | 2007-03-01 | University Of Illinois - Chicago | 5-ht2c receptor agonists as anorectic agents |
| GB0517740D0 (en) | 2005-08-31 | 2005-10-12 | Novartis Ag | Organic compounds |
| AU2006305620A1 (en) * | 2005-10-19 | 2007-04-26 | Ranbaxy Laboratories Limited | Compositions of phosphodiesterase type IV inhibitors |
| TW200745067A (en) | 2006-03-14 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| ES2335319T3 (es) | 2006-05-18 | 2010-03-24 | Syngenta Participations Ag | Nuevos microbiocidas. |
| US8198301B2 (en) | 2006-07-05 | 2012-06-12 | Hesheng Zhang | Quinazoline and quinoline derivatives as irreversibe protein tyrosine kinase inhibitors |
| AU2007275047A1 (en) | 2006-07-20 | 2008-01-24 | University Of Washington | Compositions and methods for vaccinating against HSV-2 |
| US20080161324A1 (en) | 2006-09-14 | 2008-07-03 | Johansen Lisa M | Compositions and methods for treatment of viral diseases |
| WO2008127734A2 (en) | 2007-04-13 | 2008-10-23 | The Johns Hopkins University | Lysine-specific demethylase inhibitors |
| US7906513B2 (en) | 2007-04-26 | 2011-03-15 | Enanta Pharmaceuticals, Inc. | Hydrazide-containing hepatitis C serine protease inhibitors |
| HRP20141174T1 (hr) | 2007-06-27 | 2015-02-13 | Astrazeneca Ab | Derivati pirazinona i njihova uporaba za lijeäśenje bolesti pluä†a |
| TW200922569A (en) | 2007-08-10 | 2009-06-01 | Genelabs Tech Inc | Certain nitrogen containing bicyclic chemical entities for treating viral infections |
| ES2368879T3 (es) | 2007-09-17 | 2011-11-23 | Abbott Laboratories | Pirimidinas antiinfecciosas y usos de las mismas. |
| US20100016262A1 (en) | 2007-10-18 | 2010-01-21 | Yale University | Compositions and methods for reducing hepatotoxicity associated with drug administration and treating non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and associated cirrhosis |
| WO2009052078A1 (en) | 2007-10-19 | 2009-04-23 | Boehringer Ingelheim International Gmbh | Ccr10 antagonists |
| JP5517153B2 (ja) | 2007-12-26 | 2014-06-11 | 塩野義製薬株式会社 | グリコペプチド抗生物質配糖化誘導体 |
| WO2009109991A2 (en) | 2008-01-23 | 2009-09-11 | Sun Pharma Advanced Research Company Ltd., | Novel hydrazide containing tyrosine kinase inhibitors |
| ES2400173T3 (es) | 2008-01-28 | 2013-04-08 | Janssen Pharmaceutica Nv | Derivados de 6-sustituido-tio-2-amino-quinolina útiles como inhibidores de beta-secretasa (BACE) |
| KR101672884B1 (ko) | 2008-03-19 | 2016-11-04 | 오림드 파마, 인코포레이티드 | 중추신경계 질환 및 질병 치료에 유효한 신규 화합물 |
| JP5674635B2 (ja) | 2008-03-27 | 2015-02-25 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 置換された４−アミノシクロヘキサン誘導体 |
| WO2009145856A1 (en) | 2008-04-16 | 2009-12-03 | Portola Pharmaceuticals, Inc. | 2, 6-diamino-pyrimidin- 5-yl-carboxamides as syk or jak kinases inhibitors |
| WO2009145858A1 (en) | 2008-04-18 | 2009-12-03 | Travelport Operations, Inc. | Systems and methods for programmatic generation database statements |
| EP2303889A1 (en) | 2008-06-18 | 2011-04-06 | F. Hoffmann-La Roche AG | Halo-substituted pyrimidodiazepines as plkl inhibitors |
| EP2317992A2 (en) | 2008-07-24 | 2011-05-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Preventing or treating viral infection using an inhibitor of the lsd1 protein, a mao inhibitor or an inhibitor of lsd1 and a mao inhibitor |
| US8796291B2 (en) | 2008-08-01 | 2014-08-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor antagonists and partial agonists |
| US8048887B2 (en) | 2008-09-11 | 2011-11-01 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| EP2361242B1 (en) | 2008-10-17 | 2018-08-01 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
| WO2010084160A1 (en) * | 2009-01-21 | 2010-07-29 | Oryzon Genomics S.A. | Phenylcyclopropylamine derivatives and their medical use |
| WO2010085749A2 (en) | 2009-01-23 | 2010-07-29 | Northwestern University | Potent and selective neuronal nitric oxide synthase inhibitors with improved membrane permeability |
| CA2753382C (en) | 2009-02-27 | 2014-12-23 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| WO2010130796A1 (en) | 2009-05-15 | 2010-11-18 | Novartis Ag | Aryl pyridine as aldosterone synthase inhibitors |
| US8389580B2 (en) | 2009-06-02 | 2013-03-05 | Duke University | Arylcyclopropylamines and methods of use |
| EP2258865A1 (en) | 2009-06-05 | 2010-12-08 | Universitätsklinikum Freiburg | Lysine-specific demethylase 1 (LSD1) is a biomarker for breast cancer |
| JPWO2010143582A1 (ja) | 2009-06-11 | 2012-11-22 | 公立大学法人名古屋市立大学 | フェニルシクロプロピルアミン誘導体及びｌｓｄ１阻害剤 |
| EP2467359A4 (en) | 2009-08-18 | 2013-01-09 | Univ Johns Hopkins | (BIS-) UREA- AND (BIS-) THIOMINE COMPOUNDS AS EPIGENE MODULATORS OF THE LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF DISEASE TREATMENT THEREWITH |
| WO2011031934A1 (en) | 2009-09-11 | 2011-03-17 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| KR101736218B1 (ko) * | 2009-09-25 | 2017-05-16 | 오리존 지노믹스 에스.에이. | 라이신 특이적 디메틸라아제-1 억제제 및 이의 용도 |
| EP2486002B1 (en) | 2009-10-09 | 2019-03-27 | Oryzon Genomics, S.A. | Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use |
| WO2011057262A2 (en) | 2009-11-09 | 2011-05-12 | Evolva Inc. | Treatment of infections with tp receptor antagonists |
| WO2011106574A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Inhibitors for antiviral use |
| US9186337B2 (en) | 2010-02-24 | 2015-11-17 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae |
| WO2011113005A2 (en) | 2010-03-12 | 2011-09-15 | The Johns Hopkins University | Compositions and methods for combinations of oligoamines with 2-difluoromethylornithine (dfmo) |
| ES2607081T3 (es) | 2010-04-19 | 2017-03-29 | Oryzon Genomics, S.A. | Inhibidores de desmetilasa específica de lisina-1 y su uso |
| AU2011244023A1 (en) | 2010-04-20 | 2012-10-25 | Actavis Group Ptc Ehf | Novel process for preparing phenylcyclopropylamine derivatives using novel intermediates |
| EA022459B1 (ru) | 2010-04-20 | 2016-01-29 | Университа' Дельи Студи Ди Рома "Ла Сапиенца" | Производные транилципромина в качестве ингибиторов гистон деметилаз lsd1 и/или lsd2 |
| JP2013530209A (ja) | 2010-06-30 | 2013-07-25 | アクタビス・グループ・ピーティーシー・イーエイチエフ | フェニルシクロプロピルアミン誘導体の新規調製方法及びチカグレロルを調製するためのそれらの使用 |
| US9006449B2 (en) | 2010-07-29 | 2015-04-14 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as LSD1 inhibitors |
| LT2598482T (lt) * | 2010-07-29 | 2018-07-10 | Oryzon Genomics, S.A. | Demetilazės lsd1 inhibitoriai arilciklopropilamino pagrindu ir jų medicininis panaudojimas |
| US9527805B2 (en) | 2010-09-10 | 2016-12-27 | Robert A. Casero | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders |
| US20130303545A1 (en) | 2010-09-30 | 2013-11-14 | Tamara Maes | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| US9061966B2 (en) | 2010-10-08 | 2015-06-23 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
| WO2012107498A1 (en) | 2011-02-08 | 2012-08-16 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
| US20140163041A1 (en) | 2011-02-08 | 2014-06-12 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders |
| CN103857393B (zh) | 2011-03-25 | 2016-08-17 | 葛兰素史密斯克莱知识产权（第2号）有限公司 | 环丙基胺作为lsd1抑制剂 |
| WO2012156537A2 (en) | 2011-05-19 | 2012-11-22 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for thrombosis and cardiovascular diseases |
| WO2012156531A2 (en) | 2011-05-19 | 2012-11-22 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for inflammatory diseases or conditions |
| SI2776394T1 (sl) | 2011-10-20 | 2019-05-31 | Oryzon Genomics, S.A. | Spojine (hetero)aril ciklopropilamina kot inhibitorji LSD1 |
| EP3736265A1 (en) | 2011-10-20 | 2020-11-11 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
-
2011
- 2011-04-19 ES ES11723284.3T patent/ES2607081T3/es active Active
- 2011-04-19 SI SI201131034A patent/SI2560947T1/sl unknown
- 2011-04-19 MX MX2012012111A patent/MX2012012111A/es active IP Right Grant
- 2011-04-19 RU RU2012148758/04A patent/RU2599248C2/ru active
- 2011-04-19 KR KR1020127030169A patent/KR101794020B1/ko active Active
- 2011-04-19 EP EP11723284.3A patent/EP2560947B1/en active Active
- 2011-04-19 CA CA2796726A patent/CA2796726C/en active Active
- 2011-04-19 PT PT117232843T patent/PT2560947T/pt unknown
- 2011-04-19 HU HUE11723284A patent/HUE030938T2/en unknown
- 2011-04-19 JP JP2013505467A patent/JP5868948B2/ja not_active Expired - Fee Related
- 2011-04-19 HR HRP20161748TT patent/HRP20161748T1/hr unknown
- 2011-04-19 AU AU2011244325A patent/AU2011244325B2/en active Active
- 2011-04-19 WO PCT/EP2011/056279 patent/WO2011131697A1/en not_active Ceased
- 2011-04-19 BR BR122019020471-3A patent/BR122019020471B1/pt active IP Right Grant
- 2011-04-19 EP EP16187603.2A patent/EP3133059A1/en not_active Withdrawn
- 2011-04-19 RS RS20160943A patent/RS55348B1/sr unknown
- 2011-04-19 CN CN201180030177.0A patent/CN102947265B/zh active Active
- 2011-04-19 DK DK11723284.3T patent/DK2560947T3/en active
- 2011-04-19 LT LTEP11723284.3T patent/LT2560947T/lt unknown
- 2011-04-19 BR BR112012026694A patent/BR112012026694A2/pt not_active Application Discontinuation
- 2011-04-19 US US13/641,916 patent/US8722743B2/en active Active
- 2011-04-19 PL PL11723284T patent/PL2560947T3/pl unknown
-
2012
- 2012-10-11 IL IL222361A patent/IL222361A/en active IP Right Grant
-
2014
- 2014-03-27 US US14/228,083 patent/US9149447B2/en active Active
-
2015
- 2015-09-02 US US14/843,095 patent/US10202330B2/en active Active
-
2016
- 2016-12-16 CY CY20161101304T patent/CY1118344T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013525331A5 (enExample) | ||
| RU2012148758A (ru) | Лизинспецифические ингибиторы деметилазы-1 и их применение | |
| AU2015371257B2 (en) | Isoquinoline compounds for the treatment of HIV | |
| RU2012116584A (ru) | Лизинспецифические ингибиторы деметилазы-1 и их применение | |
| JP2019517487A5 (enExample) | ||
| EA201400358A1 (ru) | Замещенные n-[1-циано-2-(фенил)этил]-2-азабицикло[2.2.1]гептан-3-карбоксамидные ингибиторы катепсина с | |
| CL2017002022A1 (es) | Composiciones farmaceuticas que contienen n-(3,5-dimetilfosfeno) - n'-(1-metiletil) - n - [3-(1-metil-1h-pirazol-4-yl) quinoxalina - 6 - yl] etano -1,2 - diamina | |
| CY1121698T1 (el) | Υγρο σκευασμα για εισπνοη που περιεχει rpl554 | |
| GEP201706620B (en) | NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS | |
| ME02400B (me) | Policiklična karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba | |
| GEP201706698B (en) | Inhibitors of influenza viruses replication | |
| SI2932970T1 (en) | Antiviral therapy | |
| JP2014511892A5 (enExample) | ||
| RU2015118647A (ru) | Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr | |
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| HRP20140884T1 (hr) | Derivati fenoksipiridinilamida i njihova primjena u lijeäśenju bolesnih stanja posredovanih inhibitorima pde4 | |
| MX2022015558A (es) | Sales de clorhidrato de n-(cianometil)-4-(2-(4-morfolinofenilamino ) pirimidin-4-il) benzamida. | |
| JP2016525102A5 (enExample) | ||
| RU2011151835A (ru) | Пиразолопиримидины и родственные гетероциклы как ингибиторы киназ | |
| MX381187B (es) | Nuevo derivado de quinoleina para usarse en el tratamiento y prevencion de infecciones virales. | |
| EP4467549A3 (en) | Intermediates of n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives | |
| UA104489C2 (uk) | Сполуки для лікування дисліпідемії та споріднених хвороб | |
| EA201370166A1 (ru) | Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы | |
| SG11201901894TA (en) | Anti-influenza virus pyrimidine derivatives | |
| JP2018527301A5 (ja) | アジリジン含有ｄｎａアルキル化剤 |